Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience.

摘要: Summary.  Non-activated and activated prothrombin complex concentrates have been used successfully to treat bleeds in haemophilia patients with inhibitors, but most physicians do not consider these products as effective factor VIII/IX non-inhibitor patients. Thus, surgical procedures inhibitor performed reluctantly. We 15 minor six major invasive diagnostic or therapeutic eight congenital A two acquired haemophilia. Administration of a loading dose 100 U kg−1 FEIBA® followed by 200 U kg −1 day−1 three doses every 8 h for 3 days then tapering the daily 150–100 U kg−1, resulted no severe unexpected bleeding complications. One adverse event was observed. 69-year-old man suffered myocardial infarction third postoperative day following sigmoidectomy. He managed safely opiate analgesia, nitrates diuretics continued use FEIBA®.